Down-regulation of Bcl-2 and Bcl-xL expression with bispecific antisense treatment in glioblastoma cell lines induce cell death

被引:90
|
作者
Jiang, ZH [1 ]
Zheng, X [1 ]
Rich, KM [1 ]
机构
[1] Washington Univ, Sch Med, Dept Neurol Surg, St Louis, MO 63110 USA
关键词
apoptosis; Bcl-2; Bcl-x; bispecific antisense oligonucleotide; brain tumor; glioblastoma;
D O I
10.1046/j.1471-4159.2003.01522.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The functions of the antiapoptotic proteins Bcl-2 and Bcl-xL were examined in glioblastoma. cells, Expression of both Bcl-2 and Bcl-xL were found to be elevated in protein lysates from seven early passage cell lines derived from human glioblastoma tumors compared with non-neoplastic glial cells. Downregulation of both bcl-2 and bcl-xL expression in glioblastoma cell lines U87 and NS008 with bcl-2/bcl-xL bispecific antisense oligonucleotide resulted in spontaneous cell death. The mechanism of cell death was partially caspase-dependent. Executioner caspase 6 and caspase 7, but not caspase 3, were involved in apoptosis induced by bcl-2/bcl-xL antisense treatment. Interestingly, western blots failed to demonstrate expression of caspase 3 in two of the seven glioblastoma cell lines examined. The data support the hypothesis that Bcl-2 and Bcl-xL are important in preventing cell death in glioblastoma cells. It also suggests that there are functional pathways capable of successful completion of caspase-dependent cell death in gliomas. These findings support a potential role of bcl-2/bcl-xL bispecifc antisense oligonucleotide therapy as a treatment strategy to enhance caspase-dependent cell death in patients with glioblastoma.
引用
收藏
页码:273 / 281
页数:9
相关论文
共 50 条
  • [31] Treatment of melanoma cells with a bcl-2/bcl-xL antisense oligonucleotide induces antiangiogenic activity
    Donatella Del Bufalo
    Daniela Trisciuoglio
    Marco Scarsella
    Uwe Zangemeister-Wittke
    Gabriella Zupi
    Oncogene, 2003, 22 : 8441 - 8447
  • [32] Clarithromycin and azithromycin induce apoptosis of activated lymphocytes via down-regulation of Bcl-xL
    Mizunoe, S
    Kadota, J
    Tokimatsu, I
    Kishi, K
    Nagai, H
    Nasu, M
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2004, 4 (09) : 1201 - 1207
  • [33] HER-2 targeting by Trastuzumab (T) modulates Bcl-2 expression and potentiates apoptosis induction by Bcl-2/Bcl-XL bispecific antisense oligoinucleotides (AS-4625).
    Milella, M
    Trisciuoglio, D
    Bruno, T
    Mottolese, M
    Cianciulli, A
    Ciuffreda, L
    Fabi, A
    Cognetti, F
    Zangemeister-Wittke, U
    Del Bufalo, D
    Zupi, G
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6087S - 6087S
  • [34] EXPRESSION OF BCL-2 AND BCL-XL IN BREAST-CANCER
    CARROLL, AG
    LIPPMAN, ME
    MOLECULAR BIOLOGY OF THE CELL, 1995, 6 : 1439 - 1439
  • [35] Trastuzumab down-regulates Bcl-2 expression and potentiates apoptosis induction by Bcl-2/Bcl-XL bispecific antisense oligonucleotides in HER-2 gene-amplified breast cancer cells
    Milella, M
    Trisciuoglio, D
    Bruno, T
    Ciuffreda, L
    Motolese, M
    Cianciulli, A
    Cognetti, F
    Zangemeister-Wittke, U
    Del Bufalo, D
    Zupi, G
    CLINICAL CANCER RESEARCH, 2004, 10 (22) : 7747 - 7756
  • [36] Human mast cell apoptosis is regulated through Bcl-2 and Bcl-XL
    Mekori, YA
    Gilfillan, AM
    Akin, C
    Hartmann, K
    Metcalfe, DD
    JOURNAL OF CLINICAL IMMUNOLOGY, 2001, 21 (03) : 171 - 174
  • [37] Human Mast Cell Apoptosis Is Regulated Through Bcl-2 and Bcl-XL
    Yoseph A. Mekori
    Alasdair M. Gilfillan
    Cem Akin
    Karin Hartmann
    Dean D. Metcalfe
    Journal of Clinical Immunology, 2001, 21 : 171 - 174
  • [38] A functionally improved locked nucleic acid antisense oligonucleotide inhibits Bcl-2 and Bcl-xL expression and facilitates tumor cell apoptosis
    Simoes-Wüst, AP
    Hopkins-Donaldson, S
    Sigrist, B
    Belyanskaya, L
    Stahel, RA
    Zangemeister-Wittke, U
    OLIGONUCLEOTIDES, 2004, 14 (03) : 199 - 209
  • [39] Bcl-xL antisense treatment sensitizes Bcl-xL-overexpressing squamous cell carcinoma cells to carboplatin
    Itoh, M
    Noutomi, T
    Chiba, H
    Mizuguchi, J
    ORAL ONCOLOGY, 2002, 38 (08): : 752 - 756
  • [40] Selective induction of apoptosis by treatment with arsenic trioxide plus rituximab in B-cell lymphoma cells is mediated by production of ROS and down-regulation of Bcl-2/Bcl-XL
    Xia, Lijuan
    Waxman, Samuel
    Jing, Yongkui
    CANCER RESEARCH, 2009, 69